Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
about
Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signaturesMolecular Imaging of Biomarkers in Breast CancerELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor CellsFifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomyAdjuvant breast cancer chemotherapy during late-trimester pregnancy: not quite a standard of careRandomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies.Triple-negative breast cancer: role of specific chemotherapy agentsKi67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancerPrognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients.Neoadjuvant Endocrine Therapy in Breast CancerFeasibility of breast conservation after neoadjuvant taxene based chemotherapy in locally advanced breast cancer: a Prospective Phase I trial.Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.Factors affecting receipt of chemotherapy in women with breast cancer.CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer.An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer.Evaluation and Validation of Neo-Adjuvant Response Index (NRI) and It's Correlation with Various Predictive Biomarkers and RECIST in Locally Advanced Breast CancerEstrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.Genes dysregulated to different extent or oppositely in estrogen receptor-positive and estrogen receptor-negative breast cancers.CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.The changing role of pathology in breast cancer diagnosis and treatment.Estrogen receptor-negative breast ductal carcinoma: clinicopathological features and MIB-1 (Ki-67) proliferative index associationBisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer.EPMA position paper in cancer: current overview and future perspectives.Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancerAllelic imbalance at the HER2/TOP2A locus in breast cancerERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled TrialsTumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.Letrozole in the neoadjuvant setting: the P024 trial.Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast CancerPrediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patientsERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosisApplication of DNA microarray technology in determining breast cancer prognosis and therapeutic response.Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer.Biomarkers in Breast Cancer - An Update
P2860
Q24812541-B978E06A-C570-4807-8F50-3A9F943DB651Q26772870-5F631E15-B691-4357-98A6-AD8C4458BF5EQ27345430-4374F648-ECFA-43E2-AC35-40E2C6EC0812Q28270514-C5863C6F-9059-4737-885C-D2542EEF9190Q28300092-C197D78A-BE5F-4004-8A93-307B776A407FQ33286192-42913662-F7DC-454D-9920-1EF5B6D22DD2Q33561131-DEA13B6A-6EC0-45AA-9E75-6513C9987B61Q33659361-53252DD4-0987-4C66-BD81-DA943CF9E509Q33759404-1753589E-5C62-4E56-AC03-81F50EBD7B67Q33770298-A08973CE-7F65-4B72-8055-672165EEDDE4Q33900930-EFEB8410-66B1-4715-A7EB-394B0B09E6DFQ34012047-DE726124-DCFF-4341-BC70-16CF82618F4EQ34029132-23D44F5B-72B2-4488-8832-17C051420E92Q34096272-253A0240-76ED-4669-80F5-C70506213814Q34117012-AD6FAC58-7B11-4719-924B-EE6643E29CA3Q34197501-73C19D32-E437-4589-867F-F3931D795322Q34272100-C572B20A-7719-4C9D-B320-B9F9F604F72DQ34438511-4D254621-5F24-41B6-AF5D-7EC511B13506Q34514808-58100F49-3FC9-47D7-98D5-C78531AA83FAQ34534308-0CD0F36D-E0AE-400F-BECF-47B58C0BC5C4Q34601123-922BA435-5563-4CCB-B4A3-262CCD5B35ECQ34854816-61EDABF3-B392-4C5E-9FEA-8685FBFD66A1Q35064727-1D2B9F01-7BA2-4A7A-AE43-07489A39BC33Q35082260-A8A0D203-C0C9-495F-878F-8C260A9BE1DEQ35106790-53CDE075-6A96-43CB-B119-C291F76B2CB2Q35172721-7414B018-658B-4977-B8FC-3E84ADA3BADDQ35532215-17E283CA-BA7F-4911-9B0A-13A0469A86B7Q35599471-D3DEE35B-662F-4F66-A2D1-E109232213CAQ35653510-52E893C6-6987-4FCE-A7F0-390E1009C136Q35663036-EB78EDB2-AAA5-4EA3-85AD-3E61B5B2904DQ35823740-282000DE-42F9-4D99-B327-A77FEBBF541AQ35881780-DE63F269-CE3D-476D-8009-16A1FE6B0C94Q35889643-ADCA4E66-83DE-4027-A4F2-31C896024924Q36026549-1949D923-0FF2-4E28-A3C5-9BA84CF4FEBFQ36055084-1B888E69-A2D2-4F1D-A67E-D0260777EE1CQ36117673-73DDCA66-A826-419B-A6BB-A217EF73C69AQ36175526-2D7CA1F6-8FFC-4CC2-9098-124510434C95Q36210870-B13810AD-F3E9-4FD3-B1F0-F4043146F958Q36225020-6E577DE8-DBF2-42EB-A103-2009019AA3C6Q36295142-198A5AE8-AAB1-4A2A-85E4-82028DEA77C5
P2860
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Chemotherapy is more effective ...... udy of preoperative treatment.
@en
Chemotherapy is more effective ...... udy of preoperative treatment.
@nl
type
label
Chemotherapy is more effective ...... udy of preoperative treatment.
@en
Chemotherapy is more effective ...... udy of preoperative treatment.
@nl
prefLabel
Chemotherapy is more effective ...... udy of preoperative treatment.
@en
Chemotherapy is more effective ...... udy of preoperative treatment.
@nl
P2093
P1476
Chemotherapy is more effective ...... udy of preoperative treatment.
@en
P2093
Alberto Luini
Aron Goldhirsch
David Zahrieh
Franco Nolè
Giancarlo Pruneri
Giulia Peruzzotti
Giuseppe Curigliano
Giuseppe Renne
Marco Colleoni
Mattia Intra
P304
P356
10.1158/1078-0432.CCR-04-0380
P407
P577
2004-10-01T00:00:00Z